181 related articles for article (PubMed ID: 31202518)
1. Blastemal NCAM
Raved D; Tokatly-Latzer I; Anafi L; Harari-Steinberg O; Barshack I; Dekel B; Pode-Shakked N
Pathol Res Pract; 2019 Aug; 215(8):152491. PubMed ID: 31202518
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
[TBL] [Abstract][Full Text] [Related]
3. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
[TBL] [Abstract][Full Text] [Related]
4. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
[TBL] [Abstract][Full Text] [Related]
5. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.
Pode-Shakked N; Metsuyanim S; Rom-Gross E; Mor Y; Fridman E; Goldstein I; Amariglio N; Rechavi G; Keshet G; Dekel B
J Cell Mol Med; 2009 Aug; 13(8B):1792-1808. PubMed ID: 20187302
[TBL] [Abstract][Full Text] [Related]
6. Wilms' tumor blastemal stem cells dedifferentiate to propagate the tumor bulk.
Shukrun R; Pode-Shakked N; Pleniceanu O; Omer D; Vax E; Peer E; Pri-Chen S; Jacob J; Hu Q; Harari-Steinberg O; Huff V; Dekel B
Stem Cell Reports; 2014 Jul; 3(1):24-33. PubMed ID: 25068119
[TBL] [Abstract][Full Text] [Related]
7. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
Sehic D; Karlsson J; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
[TBL] [Abstract][Full Text] [Related]
8. Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution.
Roth J; Blaha I; Bitter-Suermann D; Heitz PU
Am J Pathol; 1988 Dec; 133(3):596-608. PubMed ID: 2849302
[TBL] [Abstract][Full Text] [Related]
9. Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group.
Koshinaga T; Takimoto T; Okita H; Tanaka Y; Inoue E; Oue T; Nozaki M; Tsuchiya K; Haruta M; Kaneko Y; Fukuzawa M
Pediatr Int; 2019 Apr; 61(4):351-357. PubMed ID: 30786111
[TBL] [Abstract][Full Text] [Related]
10. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
[TBL] [Abstract][Full Text] [Related]
11. The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China.
Huang J; Zhang Y; Zhen Z; Lu S; Zhu J; Wang J; Sun F; Liu Z; Gao Y; Li H; Zhang Y; Sun X
Pediatr Blood Cancer; 2020 Nov; 67(11):e28567. PubMed ID: 32813315
[TBL] [Abstract][Full Text] [Related]
12. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.
Natrajan R; Reis-Filho JS; Little SE; Messahel B; Brundler MA; Dome JS; Grundy PE; Vujanic GM; Pritchard-Jones K; Jones C
Cancer Res; 2006 Dec; 66(23):11148-55. PubMed ID: 17145858
[TBL] [Abstract][Full Text] [Related]
13. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma.
Ghanem MA; Van Der Kwast TH; Den Hollander JC; Sudaryo MK; Mathoera RB; Van den Heuvel MM; Noordzij MA; Nijman RJ; van Steenbrugge GJ
Cancer; 2001 Dec; 92(12):3120-9. PubMed ID: 11753991
[TBL] [Abstract][Full Text] [Related]
19. The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets.
Pode-Shakked N; Shukrun R; Mark-Danieli M; Tsvetkov P; Bahar S; Pri-Chen S; Goldstein RS; Rom-Gross E; Mor Y; Fridman E; Meir K; Simon A; Magister M; Kaminski N; Goldmacher VS; Harari-Steinberg O; Dekel B
EMBO Mol Med; 2013 Jan; 5(1):18-37. PubMed ID: 23239665
[TBL] [Abstract][Full Text] [Related]
20. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
Ortiz MV; Ahmed S; Burns M; Henssen AG; Hollmann TJ; MacArthur I; Gunasekera S; Gaewsky L; Bradwin G; Ryan J; Letai A; He Y; Naranjo A; Chi YY; LaQuaglia M; Heaton T; Cifani P; Dome JS; Gadd S; Perlman E; Mullen E; Steen H; Kentsis A
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
